# Table 15.10
# Immunosuppression Use for Maintenance by Regimen
# Two Years Following Transplantation, 1999 to 2007
# Recipients with Kidney-Pancreas Transplants

| | Transplant Year | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 |
| **Transplants** | 941 | 915 | 891 | 906 | 871 | 881 | 903 | 924 | 864 |
| **Functioning Graft at 2 Years PostTx** | 815 | 797 | 748 | 779 | 746 | 752 | 785 | 781 | 749 |
| **With Maintenance Use Recorded at 2 Years PostTx** | 784 | 781 | 721 | 768 | 736 | 742 | 654 | 561 | 553 |
| CyA | 0.0% | 0.0% | 0.1% | 0.4% | 0.0% | 0.0% | 0.2% | 0.2% | 0.0% |
| Tac | 0.1% | 0.3% | 1.8% | 2.5% | 1.4% | 1.5% | 2.3% | 3.0% | 1.4% |
| --- + MMF/MPA | 0.0% | 0.0% | 0.1% | 0.0% | 0.3% | 0.4% | 0.0% | 0.2% | 0.2% |
| CyA + MMF/MPA | 0.0% | 0.0% | 0.3% | 0.3% | 0.4% | 0.4% | 0.8% | 0.9% | 0.7% |
| Tac + MMF/MPA | 2.4% | 3.7% | 5.3% | 6.0% | 7.3% | 13.7% | 15.6% | 17.5% | 20.1% |
| CyA + OtherAntimet | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Tac + OtherAntimet | 0.5% | 0.1% | 0.0% | 0.3% | 0.1% | 0.4% | 0.2% | 0.0% | 0.0% |
| Tac + MMF/MPA + OtherAntimet | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% |
| --- + Siro/Evero | 0.0% | 0.0% | 0.1% | 0.4% | 0.1% | 0.1% | 0.2% | 0.4% | 0.4% |
| CyA + Siro/Evero | 0.1% | 0.1% | 0.3% | 0.3% | 1.2% | 1.9% | 2.3% | 2.9% | 2.5% |
| Tac + Siro/Evero | 0.4% | 3.3% | 7.6% | 8.2% | 9.4% | 5.8% | 7.0% | 2.9% | 2.5% |
| --- + MMF/MPA + Siro/Evero | 0.0% | 0.0% | 0.4% | 0.3% | 1.8% | 4.6% | 1.7% | 1.1% | 0.9% |
| CyA + MMF/MPA + Siro/Evero | 0.1% | 0.3% | 0.0% | 0.0% | 0.0% | 0.1% | 0.2% | 0.0% | 0.0% |
| Tac + MMF/MPA + Siro/Evero | 0.0% | 0.3% | 1.0% | 0.4% | 1.1% | 0.9% | 0.9% | 3.6% | 3.6% |
| --- + Steroids | 0.3% | 0.0% | 0.8% | 0.8% | 0.5% | 0.1% | 0.2% | 0.4% | 0.5% |
| CyA + Steroids | 1.0% | 1.3% | 1.0% | 0.1% | 0.4% | 0.4% | 0.2% | 0.7% | 0.4% |
| Tac + Steroids | 7.5% | 6.0% | 5.1% | 4.9% | 4.8% | 2.7% | 4.1% | 6.4% | 5.2% |
| --- + MMF/MPA + Steroids | 0.5% | 0.3% | 0.8% | 0.9% | 0.0% | 1.1% | 0.2% | 0.0% | 0.0% |
| CyA + MMF/MPA + Steroids | 19.4% | 11.0% | 9.3% | 8.3% | 7.3% | 3.4% | 3.2% | 1.6% | 3.3% |
| Tac + MMF/MPA + Steroids | 55.9% | 53.1% | 46.9% | 49.1% | 51.2% | 52.0% | 52.3% | 49.6% | 50.8% |
| --- + OtherAntimet + Steroids | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% |
| CyA + OtherAntimet + Steroids | 0.1% | 0.1% | 0.1% | 0.4% | 0.0% | 0.3% | 0.0% | 0.0% | 0.4% |
| Tac + OtherAntimet + Steroids | 3.3% | 2.8% | 0.8% | 2.5% | 1.9% | 1.5% | 1.5% | 1.4% | 2.4% |
| --- + Siro/Evero + Steroids | 0.6% | 0.5% | 0.3% | 0.4% | 0.7% | 0.1% | 0.6% | 0.0% | 0.7% |
| CyA + Siro/Evero + Steroids | 0.9% | 2.6% | 2.6% | 0.9% | 1.5% | 0.3% | 0.3% | 0.4% | 0.5% |
| Tac + Siro/Evero + Steroids | 2.0% | 6.4% | 11.2% | 8.7% | 5.0% | 5.4% | 3.8% | 3.7% | 1.6% |
| Other Regimen | 4.7% | 7.6% | 3.9% | 4.0% | 3.5% | 2.7% | 2.4% | 3.4% | 1.6% |

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

Percentages are calculated based on the total number of patients with maintenance use at two years following transplantation. They sum to 100 percent for each column.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.